Share on StockTwits

Research analysts at Paradigm Capital increased their price target on shares of Prometic Life Sciences (TSE:PLI) from C$2.80 to C$2.90 in a report released on Wednesday. The firm currently has a “buy” rating on the stock. Paradigm Capital’s target price points to a potential upside of 124.81% from the stock’s previous close.

A number of other firms have also recently commented on PLI. Analysts at Panmure Gordon initiated coverage on shares of Prometic Life Sciences in a research note on Wednesday, August 6th. They set a “buy” rating on the stock. Analysts at Canaccord Genuity raised their price target on shares of Prometic Life Sciences from C$2.00 to C$2.25 in a research note on Friday, July 11th. They now have a “buy” rating on the stock.

Shares of Prometic Life Sciences (TSE:PLI) traded up 6.20% during mid-day trading on Wednesday, hitting $1.37. 2,327,416 shares of the company’s stock traded hands. Prometic Life Sciences has a 52-week low of $0.46 and a 52-week high of $1.65. The stock has a 50-day moving average of $1.15 and a 200-day moving average of $1.21. The company’s market cap is $656.5 million.

ProMetic Life Sciences Inc (TSE:PLI) is a bio-pharmaceutical comnpany offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, The Company focuses its activities in two segments: protein technologies and therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.